gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE · GKOSHealthcareSurgical Instruments

Glaukos Corporation (GKOS)

$246.70+5.86%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$246.70▲ 187.03% in range
Nov 4, 2025Low $81.79 · High $246.70Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Glaukos closed at $246.70 on Nov 4, up 5.86% — matching its 52-week closing high. Volume of 2.1M shares was 1.08× its 20-day average (close to normal).

Split-adjusted performance: +52.7% over one month, +82.4% over six months, +182.3% over one year.

In the quarter ended Sep 30, 2026, revenue was $211.03M, up 58.0% from a year earlier, with a net margin of 1.0%.

Short interest was 4.3M shares at the Oct 15 settlement, up 12.8% from the prior report (7.8% of float, 4.0 days to cover).

Market cap$14.60B59.2M shares
Revenue · quarter$211.0M+58.0% YoY
Diluted EPS$0.03—
P/E · TTM—P/S 21.2×
Net margin1.0%Gross 85.2%
Dividend yieldNone
52-week range81.79 – 246.700.0% from high
Volume2.1M1.08× 20-day avg
Volatility · 60d70.1%Annualised
Short % of float7.8%4.0 days to cover
Net cash$269.8MCash $336.7M
Next earnings—Not scheduled
Split-adjusted performance
1W +36.0%1M +52.7%3M +44.3%6M +82.4%YTD +118.5%1Y +182.3%3Y +269.2%5Y +476.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum89
Revenue growth93
Net margin64
Value (low P/E)—
Size92

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short4.3M+12.8% vs prior
Days to cover4.0Settled Oct 15
% of float7.8%
Short vol. 10d56.3%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
GKOSGlaukos$246.70+5.86%+82.4%+58.0%1.0%—$14.60B
SOLVSolventum$89.35+5.42%+25.9%+2.2%4.2%10.6$15.21BCompare
BAXBaxter International$26.50+3.96%+56.1%+5.0%9.9%—$13.71BCompare
PENPenumbra$322.45+0.76%−0.5%+15.6%10.3%80.9$12.71BCompare
GMEDGLOBUS MEDICAL$87.10+9.45%−2.4%+5.9%19.2%21.8$11.69BCompare
PODDInsulet$165.02+6.56%+9.1%+23.5%11.8%30.5$11.44BCompare
WSTWest Pharmaceutical Services$408.78+0.44%+30.8%+8.7%24.5%44.6$28.48BCompare
DXCMDexCom$88.48+6.64%+46.6%+11.2%20.5%33.3$33.00BCompare
TFXTeleflex Incorporated$149.87+7.09%+21.6%+28.9%17.5%—$6.35BCompare

News about Glaukos

All news →
Glaukos (GKOS) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research · Oct 28, 2026▲ PositiveCompared to Estimates, Glaukos (GKOS) Q3 Earnings: A Look at Key MetricsZacks Investment Research · Oct 28, 2026▲ PositiveGlaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?Zacks Investment Research · Oct 14, 2026▲ PositiveGlaukos Strengthens Retinal Pipeline Through RevOpsis Licensing DealZacks Investment Research · Oct 9, 2026▲ PositiveGlaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?The Motley Fool · Jul 14, 2026▲ Positive

Quick answers

What does Glaukos do?
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time.
What is GKOS's market cap?
$14.60B, based on the Nov 4 close of $246.70.
Does Glaukos pay a dividend?
No regular cash dividend has been paid in the last year.
How much of GKOS is sold short?
4.3M shares, 7.8% of float, as of Oct 15, 2026.
What sector is GKOS in?
Healthcare, in the Surgical Instruments industry.

About Glaukos

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

HQ: Aliso Viejo, CA1,094 employeesListed Jun 25, 2015glaukos.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology